Cefotaxime And Dextrose 2.4% In Plastic Container
(Cefotaxime)ApprovedSmall molecule
Cefotaxime And Dextrose 2.4% In Plastic Container is one of 172 small molecule programs targeting Brain Injury. It is currently in Approved.
6
Indications
14
Total Trials
2
Active Trials
171
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Cefotaxime And Dextrose 2.4% In Plastic Container
SSterimax
Approved
Corlanor
AmgenPreclinical
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Primaxin
PfizerPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Aquasol a
BBandim Health Project
Preclinical
Micardis
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Peritonitis3 trials
Cirrhosis1 trial
Ciprofloxacin1 trial
7 more indications
CAR1 trial
Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)
Unknown status·—·Phase 4·NCT03922919·250 enrolled
Treatment1 trial
Meropenem vs Cefotaxime as Empirical Treatment of SBP
Unknown status·—·Phase 4·NCT05427747·286 enrolled
Urinary Tract Infection1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
CLAFORAN
NDA NDA050547
May 20, 1985
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
NDA NDA050596
Jul 29, 2004
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER
NDA NDA050792
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefotaxime. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]